This excerpt taken from the GSK 6-K filed Jul 25, 2007.
Total pharmaceutical turnover was level at £4.8 billion. In the United States, turnover fell 2% to £2.3 billion, impacted by continued generic competition to Zofran and Wellbutrin XL and a decline in Avandia sales.
In Europe turnover was up 1% to £1.4 billion, with sales growth of newer products offsetting generic competition to older products and further price cuts mandated by European governments. Sales in International were £1 billion, up 3%, with growth impacted by lower sales of Avandia in some markets and a reduction in vaccine tender orders.